

Supplemental Material

Supplemental Tables

Supplemental Table 1: Sensitivity Analyses

	N	Hazard Ratio	P-Value
Primary Analysis	27,564	0.71 (0.50-1.00)	0.051
Patients on anticoagulation at baseline removed	25,343	0.67 (0.46-0.97)	0.035
Patients on anticoagulation at baseline removed except those with history of atrial fibrillation	26,647	0.67 (0.46-0.96)	0.032
Total Events Analysis	27,564	0.71 (0.49-1.02)	0.067
Total events analysis with patients on anticoagulation at baseline removed	25,343	0.65 (0.44-0.95)	0.028
Total events analysis with patients on anticoagulation at baseline removed except those with history of atrial fibrillation	26,647	0.66 (0.45-0.96)	0.033
Patients with preceding ASCVD Events during the trial removed*	27,557	0.73 (0.51-1.04)	0.083

**There were no ASCVD events in the 50 days preceding any VTE events. The median time between ASCVD event and VTE was 492 days.*

ASCVD = atherosclerotic cardiovascular disease; N = sample size

Supplemental Table 2: Genetic Cohort vs Overall Trial Cohort

	Trial Population <i>N=27,564</i>	Genetic Cohort <i>N=14,298</i>
Demographics		
Age (yr) (+/-SD)	62.5 (9.0)	62.9 (8.8)
Male (%)	20795 (75)	10906 (76)
Obesity (BMI>30) (%)	10942 (40)	6043 (42)
Medical History (%)		
Myocardial infarction	22351 (81)	11688 (82)
Ischemic stroke	5337 (19)	2505 (18)
Peripheral artery disease	3642 (13)	2102 (15)
Hypertension	22084 (80)	11495 (80)
Diabetes mellitus	10081 (37)	4691 (33)
Heart Failure	6394 (23.2)	3400 (23.8)
Current cigarette use	7777 (28)	4171 (29)
Median lipid measures (IQR)		
LDL cholesterol — mg/dl	91.5 (79.5-108.5)	92.0 (80.0-109.0)
Total cholesterol — mg/dl	167.5 (151.0-188.5)	169.0 (152.5-190.0)
HDL cholesterol — mg/dl	44.0 (37.0-52.5)	45.0 (38.0-53.5)
Triglycerides — mg/dl	133.0 (100.0-182.0)	134.5 (101.0-184.0)
Lipoprotein(a) — nmol/L	37.0 (13.0-165.0)	33.0 (11.0-162.0)


BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; IQR, interquartile range; SD, standard deviation; Yr, years.

Supplemental Table 3: Sensitivity analysis for Risk Prediction of the Genetic Risk Score with Lp(a) included in the model

	HR per 1-SD	P-Value	Top 3rd	P-Value
Primary Model	1.57 (1.23-2.00)	<0.0001	2.31 (1.26-4.25)	0.007
Lp(a) added	1.51 (1.17-1.96)	0.002	2.18 (1.16-4.09)	0.015

Supplemental Figures

Supplemental Figure 1: Association of Baseline Biomarkers with VTE in the Placebo Arm



Supplemental Figure 2: Meta-Regression of the Reduction in Lp(a) and Effect on VTE. Each circle represents a quartile of baseline Lp(a). The dashed lines represent 95% confidence intervals.

